These mice allowed the authors to examine the effect of loss of PGI or TXA action on atherosclerosis development. Relative to apoE–/– mice, the apoE–/–IP–/– mice had accelerated initiation and development of athero-sclerosis, while the apoE–/–TP–/– mice had delayed development. apoE–/–IP–/– mice also demonstrated other mark-ers of more severe disease, compared with apoE–/– mice. apoE–/–TP–/– mice presented with fewer markers of dis-ease. These data indicate that PGI2 protects against and TXA2 promotes atherosclerosis development. The use of TP antagonists and molecules with PG-like activity may therefore aid in atherosclerosis prevention. Furthermore these data fit well with previous work that indicated that low doses of aspirin, which inhibits TXA2 more than PGI2, has been used as anti-platelet therapy for the prevention of myocardial infarction and recurrence of strokes.
TITLE: Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice
AUTHOR CONTACT:
Shuh Narumiya
Kyoto University Faculty of Medicine, Yoshida, Sakyoku, Kyoto 606-8501, Japan
Phone: 81-75-753-4392; Fax: 81-75-753-4693; E-mail: snaru@mfour.med.kyoto-u.ac.jp
View the PDF of this article at: http://www.jci.org/cgi/content/full/114/6/784
Journal
Journal of Clinical Investigation